CT PERFUSION IMAGING USING IODINATED LIPOSOMES

使用碘化脂质体进行 CT 灌注成像

• 批准号: 7358274
• 负责人: SRINIVASAN MUKUNDAN
• 金额: $ 1.54万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2007-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7358274
• 关键词: CT; PERFUSION; IMAGING; USING; IODINATED

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary goal of this proposal is to overcome the confounding effects of a leaky blood brain barrier in tumors by using a novel CT contrast agent, iodinated liposome. Liposomes are microscopic spherical vesicles constructed of phospholipid bilayers that can encapsulate the iodinated contrast agent. Vesicle size, chemical affinity, and thermal (or pH) sensitivities can be engineered. We will use polyethylene glycol (PEG)-coated liposome with an intravascular circulation half-life of 6-8 hours. These characteristics allow blood pool imaging for several hours after a simple IV injection, and should also decrease the rate of extravasation of the agent into the tumor interstitium. The relative enhancement of a voxel on a CT study is proportional to the intravoxel concentration of contrast agent. Agents that behave as true bloodpool agents on the time scale of this experiment should remain within the intravascular space. Therefore, relative enhancement of a voxel should be proportional to the cerebral blood volume (CBV). This should allow for direct measurement of CBV, rather than the need for using a deconvolution approach. Moreover, reinjection with a standard iodinated contrast agent can be performed soon afterward, and a more accurate permeability surface product determination can be obtained because CBV has been accurately measured.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本建议的主要目标是通过使用一种新型CT造影剂碘化脂质体来克服肿瘤中漏血脑屏障的混淆效应。脂质体是由磷脂双层构成的微小球形囊泡，可以包裹碘化造影剂。囊泡大小，化学亲和力和热（或pH值）敏感性可以被设计。我们将使用聚乙二醇（PEG）包被的脂质体，其血管内循环半衰期为6-8小时。这些特点使得简单的静脉注射后几个小时的血池成像成为可能，同时也降低了药物向肿瘤间质外渗的速率。在CT研究中，体素的相对增强与体素内造影剂浓度成正比。在本实验的时间尺度上表现为真正的血池剂的药物应该留在血管内空间。因此，体素的相对增强应与脑血容量（CBV）成正比。这应该允许直接测量CBV，而不需要使用反褶积方法。此外，可以很快再注射标准碘化造影剂，并且可以获得更准确的渗透性表面产物测定，因为CBV已经精确测量。